is caused by the cooperation of multiple oncogenic lesions 1,2 . We used exome sequencing on 67 T-ALLs to gain insight into the mutational spectrum in these leukemias. We detected protein-altering mutations in 508 genes, with an average of 8.2 mutations in pediatric and 21.0 mutations in adult T-ALL. Using stringent filtering, we predict seven new oncogenic driver genes in T-ALL. We identify CNOT3 as a tumor suppressor mutated in 7 of 89 (7.9%) adult T-ALLs, and its knockdown causes tumors in a sensitized Drosophila melanogaster model 3 . In addition, we identify mutations affecting the ribosomal proteins RPL5 and RPL10 in 12 of 122 (9.8%) pediatric T-ALLs, with recurrent alterations of Arg98 in RPL10. Yeast and lymphoid cells expressing the RPL10 Arg98Ser mutant showed a ribosome biogenesis defect. Our data provide insights into the mutational landscape of pediatric versus adult T-ALL and identify the ribosome as a potential oncogenic factor.
T-cell acute lymphoblastic leukemia (T-ALL) is caused by the cooperation of multiple oncogenic lesions
. We used exome sequencing on 67 T-ALLs to gain insight into the mutational spectrum in these leukemias. We detected protein-altering mutations in 508 genes, with an average of 8.2 mutations in pediatric and 21.0 mutations in adult T-ALL. Using stringent filtering, we predict seven new oncogenic driver genes in T-ALL. We identify CNOT3 as a tumor suppressor mutated in 7 of 89 (7.9%) adult T-ALLs, and its knockdown causes tumors in a sensitized Drosophila melanogaster model 3 . In addition, we identify mutations affecting the ribosomal proteins RPL5 and RPL10 in 12 of 122 (9.8%) pediatric T-ALLs, with recurrent alterations of Arg98 in RPL10. Yeast and lymphoid cells expressing the RPL10 Arg98Ser mutant showed a ribosome biogenesis defect. Our data provide insights into the mutational landscape of pediatric versus adult T-ALL and identify the ribosome as a potential oncogenic factor.
T-ALL is a genetically heterogeneous leukemia that is caused by the accumulation of multiple oncogenic lesions, which have been identified through characterization of chromosomal aberrations or via candidate gene sequencing [4] [5] [6] [7] . In addition, recent whole-genome sequencing of 12 immature early T-cell precursor (ETP) ALLs revealed several new oncogenic drivers in this T-ALL subtype 8 . To discover new disease-driving genes in pediatric and adult T-ALL, we performed exome sequencing on 67 diagnostic T-ALL samples, 39 matched remission samples and 17 T-ALL cell lines (Supplementary  Tables 1-3 and Supplementary Note).
To identify somatic mutations, we limited our initial analysis to the 39 paired samples acquired in the same individual at diagnosis and remission. To assess the performance of variant calling, 185 predicted single-nucleotide variations (SNVs) were validated by Sanger sequencing. This set was used to determine the filtering strategy with the best sensitivity and specificity. Different parameters were tested as filters, including sequencing coverage of the variant nucleotide, variant allele frequency, variant quality and presence in repeat regions. Finally, ranging thresholds of the somatic score, as calculated by SomaticSniper 9 , were used as a filter ( Supplementary  Fig. 1 ). Removing variants with a somatic score below 70 resulted in 89% sensitivity and 96% specificity. Using this filter, a second batch of SNVs was selected for testing with capillary sequencing, which confirmed 80% (67 of 84) of the predicted SNVs.
We identified 1,810 somatic SNVs and 1,248 insertion and/or deletions (indels) in the 39 diagnostic-remission pairs. Excessively high numbers of somatic indels were present in three samples, possibly owing to defective DNA repair. These indels were excluded from candidate gene detection. One-fourth of the somatic mutations were protein altering, with the majority being missense mutations (413); the rest were frameshift indels (55), in-frame indels (30) , nonsense coding (32) or splice-site mutations (39) . On average, each sample contained 14.7 somatic protein-altering SNVs and indels (Supplementary Table 4 ). Notably, adults (age of >15 years) showed 2.5 times more somatic protein-altering mutations than children (21.0 versus 8.2; P < 0.0001), and there was a clear correlation between the age of the affected individual and mutation number (Fig. 1a,b and Supplementary Fig. 2 ). However, disease outcome was not linked to mutation number (Supplementary Fig. 3 ). Notably, a larger fraction of somatic SNVs in adults were cytosine-to-thymine transitions, and adults had a lower fraction of adenine-to-guanine transitions than children (Fig. 1c,d ).
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia Protein-altering mutations occurred across 508 genes (Supplementary Table 5 ). To distinguish driver mutations from passenger ones, we only considered genes that were mutated in at least two samples and were significantly more mutated than the local background mutation rate, as calculated by Genome MuSiC 10 (Supplementary Table 6 ). We identified 15 candidate driver genes meeting these two criteria ( Fig. 2 and Table 1 ) and 11 additional genes that were recurrently but not significantly mutated ( Supplementary  Fig. 4 ). Of the 15 candidate driver genes, 8 were known drivers in T-ALL, and 7 were new. Reassuringly, we found further mutations in many of the 15 candidate driver genes across the 28 additional diagnosis samples and 17 cell lines that were sequenced (Fig. 2,  Supplementary Fig. 5 and Supplementary Table 7) .
Adult samples showed 2.7 times more mutations in candidate driver genes than children (1.9 versus 0.7; P = 0.0034) ( Supplementary  Fig. 2 ). Moreover, mutations in FBXW7, CNOT3, PHF6, KDM6A and MAGEC3 were mainly present in adults, whereas RPL10 mutations were almost exclusively found in children (Figs. 2 and 3 , Table 1 and Supplementary Tables 8-10 ). Notably, our list of candidate driver genes included RPL5 and RPL10, two genes encoding ribosomal proteins that occupy neighboring positions in the 60S ribosomal complex ( Supplementary Fig. 6 ), with five exome samples carrying the same somatic mutation encoding a p.Arg98Ser alteration in RPL10. Also, the CNOT3 gene showed evidence of a mutational hotspot, with three affected individuals carrying a substitution at Arg57 (Fig. 3a) . Screening for mutations in these 3 genes in an independent confirmation cohort of 144 T-ALLs identified additional mutations in each of these genes ( Fig. 3a and Supplementary Tables 8 and 9 ), resulting in total mutation frequencies of 3.8% (8/211) for CNOT3 and 7.1% (15/211) for RPL5 and RPL10. Adding the results from the confirmation cohort consolidated the association between CNOT3 mutations and adult age (P = 0.01), and CNOT3 was found to be mutated in 7 of 89 (7.9%) adult T-ALLs. In contrast, RPL10 mutations were associated with young age (P = 0.03), and 10 of 122 (8.2%) pediatric cases had RPL10 mutations (Fig. 3b) . Mutations in CNOT3, RPL10 or RPL5 were not associated with any of the major molecular subgroups in T-ALL or with NOTCH1 mutations (Supplementary Tables 8-10 ).
Ribosomal defects have been identified in inherited hematopoietic disorders (called ribosomopathies) that result in anemia and a propensity to develop leukemia 11 . Mutations in RPL5 have previously been associated with Diamond Blackfan anemia and were studied in much detail in that context 11 are shown. Samples with fewer than ten somatic SNVs were excluded from this analysis. The reported P values test whether there was a significant difference between adults and children and was calculated using the two-tailed Wilcoxon signed-rank test. Pediatric cases, n = 16; adult cases, n = 19.
Transcriptional regulation   TLE54  TLE57  TLE58  TLE64  TLE66  TLE76  TLE90  TLE02  TLE05  TLE07  TLE48  TLE51  TLE55  TLE56  TLE59  TLE60  TLE61  TLE62  TLE67  TLE85  TLE10  TLE109  TLE34  TLE38  TLE43  TLE44  TBR01  TBR05  TBR06  TBR08  TLE01  TLE03  TLE06  TLE08  TLE33  TLE36  TLE39  TLE40  TLE41  TLE42  TLE45  TLE47  TLE78  TLE80  TLE83  TLE84  TLE87 l e t t e r s npg l e t t e r s not been described in any disease. Notably, loss of RPL22, another 60S ribosomal protein, was also recently identified in T-ALL 12 , and, in our exome cohort, we also detected one affected individual with a frameshift mutation in RPL22 (Supplementary Table 5 ). RPL10 is located on the X chromosome, and 7 of 11 mutant cases were males carrying the mutation in nearly all leukemia cells. Moreover, the single RPL10-mutated female from whom we had RNA available expressed only the mutant allele in tumor cells (Supplementary Fig. 7 ). To confirm that these RPL10 mutations were not random passenger mutations but alter RPL10 function, we engineered yeast cells expressing wild-type Rpl10, Rpl10 Arg98Ser, Rpl10 Arg98Cys or Rpl10 His123Pro as the sole copy of Rpl10. Rpl10 has been intensively studied 13 and is highly conserved in yeast, with Arg98 being unchanged from yeast to humans ( Supplementary  Fig. 8a) . Notably, the Arg98 and His123 residues are closely apposed in a β hairpin near the peptidyltransferase center, the catalytic core of the ribosome (Supplementary Fig. 8b,c) . In yeast, expression of the Rpl10 mutants impaired proliferation and caused a ribosome biogenesis defect, evidenced by the altered ratio of mature 80S to free subunits and the reduced presence of polysomes (Fig. 4a,b and Supplementary  Fig. 9 ). In addition, Nmd3 and Tif6 showed aberrant accumulation in the cytoplasm in cells expressing Rpl10 Arg98Ser (Fig. 4c and  Supplementary Fig. 9 ), indicating that this alteration impaired the release of the 60S export adaptor Nmd3 as well as the subunit antiassociation factor Tif6. The deleterious effects of the Rpl10 mutants were partially suppressed by expressing Nmd3 Leu291Phe (Fig. 4d) , a mutant with weakened affinity for the ribosome 14 , and by increasing the dosage of the Nmd3 gene (Supplementary Fig. 9 ). These data indicate that the Rpl10 mutants affect the release of Nmd3 from the ribosome. Retention of Nmd3 and Tif6 on pre-60S subunits blocks ribosome assembly, and the resulting depletion of Nmd3 from the nucleus reduces the export of new ribosome subunits 15 . We also tested the effect of the expression of human RPL10 Arg98Ser, the most (b) Pie charts reporting mutation frequencies detected in adult versus pediatric individuals with T-ALL. All reported P values tested whether there was a significant difference in mutation frequency in adults versus children and were calculated using the unpaired t test.
npg l e t t e r s frequent RPL10 alteration, in lymphoid cells. In these cells, expression of RPL10 Arg98Ser also resulted in proliferation and ribosome biogenesis defects (Fig. 4e,f) .
In the context of CNOT3, some of the mutations we identified were clearly truncating, whereas another group of mutations seemed to represent missense mutations affecting Arg57. Analysis of mRNA expression, however, showed that, also in the cases with Arg57 alteration, the mutant transcripts were not or were only weakly expressed ( Supplementary  Fig. 7 ). This is most likely caused by splicing defects, as the mutations are located at the splice donor site of exon 5. The mutations in CNOT3 thus suggest that this gene acts as a tumor suppressor in T-ALL. CNOT3 is part of the CCR4-NOT complex that regulates gene expression transcriptionally and post-transcriptionally 16 . Cnot3 also mediates self-renewal in mouse embryonic stem cells, where Cnot3 shares many target genes with Myc 17 , a known oncogene in T-ALL. To investigate the effect of loss of CNOT3 in tumor formation, we used an established Drosophila eye cancer model. We used the sensitized model in which the Notch ligand Delta is overexpressed in the developing eyes. These flies have larger eyes but by themselves do not develop tumors 3, 7, 18, 19 , and this model is relevant for T-ALL, given the central role of NOTCH1 signaling in this disease 1 . Reduction of Not3 expression in this genetic background resulted in a marked increase in tumor incidence from 8% of the eyes with control RNA interference (RNAi) to 46% up to 90% with three different Not3 RNAi lines and one line with a P-element insertion in Not3 (Fig. 5) . These data support the notion that reduction in Not3 expression is sufficient to transform sensitized cells.
Using whole-exome sequencing, we describe clear differences between pediatric and adult T-ALL and identify a spectrum of driver mutations that function in various cellular processes. One notable observation is that a subset of T-ALL cases have accumulated mutations that affect the function of the ribosome, and it is currently unclear what advantage this might provide to the cancer cells. This is, however, very similar to recent findings of deregulated splicing in myelodysplasia and chronic lymphocytic leukemia [20] [21] [22] [23] and might indicate that cancer cells have mechanisms to overcome defects in these basic processes. Indeed, cancer cells might compensate for the deleterious effects of mutations affecting the ribosome by acquiring additional mutations, similar to the suppressive effect of the Nmd3 Leu291Phe alteration that we describe in the yeast model (Fig. 4d) . Alternatively, the mutations affecting the ribosome might downregulate the hyperactive translation machinery in cancer cells 24 , which could be beneficial for the fitness of these cells. Our data shed light on the diversity of mutations that are implicated in T-ALL development and on the differences between adult and pediatric T-ALL.
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